rethinkTHC Search
Menu
Study breakdown

CBD reduced pain sensitivity in a mouse model of Parkinson's disease

Animal StudyPreliminary evidence
The takeaway

CBD reversed the increased pain sensitivity caused by experimental parkinsonism in mice, with effects involving CB1 and TRPV1 receptors and potentially mediated through increased anandamide levels.

Parkinson's disease researchers, pain pharmacologists, CBD researchers

Both acute and chronic CBD reversed Parkinson's-related pain hypersensitivity in mice

What the researchers found

The Parkinson's model (6-OHDA) decreased thermal and mechanical pain thresholds. Both acute and chronic CBD treatment reversed this hyperalgesia and allodynia. CBD's pain-relieving effect was potentiated by a FAAH inhibitor and TRPV1 antagonist, and blocked by CB1/CB2 inverse agonist, suggesting CBD increases endogenous anandamide levels.

Why it matters

Pain is a prevalent but undertreated non-motor symptom of Parkinson's disease. CBD could offer a targeted approach if its mechanisms in this context are understood.

The numbers in context

6-OHDA model decreased both thermal and mechanical nociceptive thresholds. Acute and chronic CBD reversed both hyperalgesia and allodynia. FAAH inhibitor and TRPV1 antagonist potentiated CBD; CB1/CB2 inverse agonist blocked it.

How the study worked

Mouse model of Parkinson's (6-hydroxydopamine lesion). CBD administered acutely or chronically. Co-administration studies with FAAH inhibitor, TRPV1 antagonist, and CB1/CB2 inverse agonist to elucidate mechanisms.

What this study cannot tell us

Mouse model; 6-OHDA is a toxic model that does not fully recapitulate human Parkinson's; CBD doses used may not translate directly to human dosing; mechanism studies used pharmacological tools with potential off-target effects.

How to read the evidence

Single animal study with mechanistic dissection; 6-OHDA model has limitations for translating to human PD.

When this study was published

Published in 2020.

The bigger picture

Pain affects the majority of Parkinson's patients but has no specific pharmacotherapy. CBD's ability to restore normal pain sensitivity in this model identifies it as a candidate for further development.

Questions still open

  • Would CBD reduce pain in Parkinson's patients? Does the anandamide-mediated mechanism suggest FAAH inhibitors could complement CBD for PD pain?

Common questions

Can CBD help with Parkinson's pain?
In this mouse model, CBD effectively reversed the increased pain sensitivity caused by experimental parkinsonism. However, animal model results do not always translate to humans, and clinical trials in Parkinson's patients would be needed.
How does CBD reduce pain in this model?
The researchers found CBD's pain-relieving effect involved CB1 receptors and TRPV1 channels, and was enhanced by blocking the enzyme that breaks down anandamide (an endocannabinoid). This suggests CBD may work partly by boosting the body's own endocannabinoid system.

Read the original research

Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.

Neuropharmacology, 163, 107808

Citation

Crivelaro do Nascimento, Glauce; Ferrari, Daniele Pereira; Guimaraes, Francisco Silveira; Del Bel, Elaine Aparecida; Bortolanza, Mariza; Ferreira-Junior, Nilson Carlos. (2020). Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.. Neuropharmacology, 163, 107808. https://doi.org/10.1016/j.neuropharm.2019.107808

Explore the wider topic